 | | | | Related Healthscout Videos | |
|
TUESDAY, July 10 (HealthDay News) -- There's little hard evidence that a diet rich in tomatoes and the tomato antioxidant lycopene can ward off cancer, according to research from the U.S. Food and Drug Administration.
Reporting in the July 10 issue of the Journal of the National Cancer Institute, FDA experts lay out in great detail the evidence -- or mostly lack of it -- behind their November 2005 statement that tomato consumption is not linked to any reduction risk of tumors of the prostate, ovary, stomach and pancreas.
Text Continues Below
The agency had previously found no evidence that tomatoes could cut risks for lung, colorectal, breast, cervical or endometrial tumors, either.
The November 2005 statement contended that, "there is no credible evidence to support qualified health claims for lycopene, as a food ingredient, component or food, or as a dietary supplement, and reduced risk of any of the cancers in the petition."
The petition for approval of the claims was submitted by a supplement maker, American Longevity.
The FDA has now put the evidence behind its decision in print, said Paul Coates, director of the office of dietary supplements at the U.S. National Institutes of Health and the author of a related journal editorial.
The new data review "gives people some idea of what the process is," Coates said. That's important, he said, because "one of the things that people are concerned about is how are these decisions arrived at. Making the process transparent and open will be helpful."
As part of its review, the FDA pored over data from 107 observational studies comparing the level of consumption of either tomatoes or lycopene with people's general cancer risk. They also looked at 23 studies that focused on blood levels of lycopene, although most of those trials were deemed unreliable, either because there were too many confounding factors or because most focused on cancer patients, not healthy people.
Page: 1 | 2 | Next >>
|
.gif)
